Metagenomi Therapeutics (MGX) Return on Sales [ROS] (2023 - 2026)
Metagenomi Therapeutics' Return on Sales [ROS] was -1970.11% in Q1 2026, down 1296.01 percentage points from -674.10% a year earlier and down 1347.07 percentage points from the prior quarter.
Metagenomi Therapeutics (MGX) Return on Sales [ROS] (2023 - 2026) Analysis & Trends
On a trailing twelve-month basis, Metagenomi Therapeutics' Return on Sales [ROS] was -415.48% through Mar 31, 2026, down 221.74 percentage points year-over-year; for FY2025, it came in at -380.85%, down 210.85 percentage points from FY2024.
- In earlier years, Return on Sales [ROS] was -170.00% in FY2024 (+5.38 pp) and -175.38% in FY2023.
- The Q1 2026 figure marks the lowest quarterly Return on Sales [ROS] in data going back to Q1 2023.
- Compared with a year earlier, Return on Sales [ROS] has declined for seven straight quarters, with an average year-over-year change of -292.60 percentage points over the last eight quarters.
- The best year-over-year quarter for Return on Sales [ROS] over five years was Q2 2024 (a gain of 74.16 percentage points); the worst was Q1 2026 (a drop of 1296.01 percentage points).
- Per Business Quant data, MGX's Return on Sales [ROS] in the three quarters before Q1 2026 was -623.04% (Q4 2025), -263.76% (Q3 2025) and -246.53% (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 51.16% |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 28.21% |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 37.86% |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | -3.52% |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 32.97% |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 20.57% |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 34.95% |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -133.21% |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 28.37% |
| 10 | Metagenomi Therapeutics | 38.53 Mn | 38.53 Mn | - | - |
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -1,970.11% |
| Dec 31, 2025 | -623.04% |
| Sep 30, 2025 | -263.76% |
| Jun 30, 2025 | -246.53% |
| Mar 31, 2025 | -674.10% |
| Dec 31, 2024 | -214.51% |
| Sep 30, 2024 | -194.40% |
| Jun 30, 2024 | -84.28% |
| Mar 31, 2024 | -260.17% |
| Dec 31, 2023 | -162.88% |
| Sep 30, 2023 | -181.15% |
| Jun 30, 2023 | -158.45% |
| Mar 31, 2023 | -207.21% |
Metagenomi Therapeutics Return on Sales [ROS] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=MGX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-sales-[ros]", "ticker": "MGX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=MGX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();